Safe and sustained vaginal delivery of pyrimidinedione HIV-1 inhibitors from polyurethane intravaginal rings

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 3, 2012, Pages 1291-1299

  Johnson, Todd J ^a   Srinivasan, Priya ^b   Albright, Theodore H ^a   Watson Buckheit, Karen ^c   Rabe, Lorna ^d   Martin, Amy ^b   Pau, Chou Pong ^b   Hendry, R Michael ^b   Otten, Ron ^b   McNicholl, Janet ^b   Buckheit, Robert ^c   Smith, James ^b   Kiser, Patrick F ^a  

^a Department of Electrical and Computer Engineering   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c ImQuest Biosciences   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; IQP 0528; IQP 0532; POLYURETHAN; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; DRUG STABILITY; DRUG STRUCTURE; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; VAGINA DISCHARGE; VAGINA FLORA; VAGINA RING;

EID: 84863173866     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05721-11     Document Type: Article

References (47)

1. Abdool Karim Q, et al. 2010. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329:1168-1174.
2. Bravo Gonzalez RC, Boess F, Durr E, Schaub N, Bittner B. 2004. In vitro investigation on the impact of Solutol HS 15 on the uptake of colchicine into rat hepatocytes. Int. J. Pharm. 279:27-31. (Pubitemid 38968639)
3. Buckheit RW, Jr, et al. 1994. Biological and biochemical anti-HIV activity of the benzothiadiazine class of nonnucleoside reverse transcriptase inhibitors. Antiviral Res. 25:43-56.
4. Buckheit RW, Jr, Hartman TL, Watson KM, Chung SG, Cho EH. 2008. Comparative evaluation of the inhibitory activities of a series of pyrimidinedione congeners that inhibit human immunodeficiency virus types 1 and 2. Antimicrob. Agents Chemother. 52:225-236.
5. Buckheit RW, Jr, et al. 2007. The structure-activity relationships of 2,4(1H,3H)-pyrimidinedione derivatives as potent HIV type 1 and type 2 inhibitors. Antivir. Chem. Chemother. 18:259-275.
6. Chien YW, Lambert HJ. 1974. Controlled drug release from polymeric delivery devices. II. Differentiation between partition-controlled and matrix-controlled drug release mechanisms. J. Pharm. Sci. 63:515-519.
7. Chien YW, Lin S. 2002. Optimisation of treatment by applying programmable rate-controlled drug delivery technology. Clin. Pharmacokinet. 41: 1267-1299. (Pubitemid 36026766)
8. Clarke JG, et al. 2002. Microflora changes with the use of a vaginal microbicide. Sex. Transm. Dis. 29:288-293. (Pubitemid 34477918)
9. Cone RA. 2009. Barrier properties of mucus. Adv. Drug Deliv. Rev. 61: 75-85.
10. Cu Y, Saltzman WM. 2009. Mathematical modeling of molecular diffusion through mucus. Adv. Drug Deliv. Rev. 61:101-114.
11. Geonnotti AR, Katz DF. 2010. Compartmental transport model of microbicide delivery by an intravaginal ring. J. Pharm. Sci. 99:3514-3521.
12. Grant RM, et al. 2008. Whither or wither microbicides? Science 321:532-534.
13. Gunawardana M, et al. 2011. Microbial biofilms on the surface of intravaginal rings worn in non-human primates. J. Med. Microbiol. 60:828-837.
14. Gupta KM, et al. 2008. Polyurethane intravaginal ring for controlled delivery of dapivirine, a nonnucleoside reverse transcriptase inhibitor of HIV-1. J. Pharm. Sci. 97:4228-4239.
15. Hardy E, Hebling EM, Sousa MH, Almeida AF, Amaral E. 2007. Delivery of microbicides to the vagina: difficulties reported with the use of three devices, adherence to use and preferences. Contraception 76:126-131. (Pubitemid 47082515)
16. Heise LL, et al. 2011. Apples and oranges? Interpreting success in HIV prevention trials. Contraception 83:10-15.
17. Helbling IM, Luna JA, Cabrera MI. 2011. Mathematical modeling of drug delivery from torus-shaped single-layer devices. J. Control. Release 149:258-263.
18. Hladik F, Hope TJ. 2009. HIV infection of the genital mucosa in women. Curr. HIV/AIDS Rep. 6:20-28.
19. Huynh-Ba K (ed). 2009. Handbook of stability testing in pharmaceutical development. Springer, New York, NY.
20. Iyer SS, Barr WH, Karnes HT. 2006. Profiling in vitro drug release from subcutaneous implants: a review of current status and potential implications on drug product development. Biopharm. Drug Dispos. 27:157-170. (Pubitemid 43797112)
21. Johnson TJ, Gupta KM, Fabian J, Albright TH, Kiser PF. 2010. Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir. Eur. J. Pharm. Sci. 39:203-212.
22. Klasse PJ, Shattock R, Moore JP. 2008. Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission. Annu. Rev. Med. 59:455-471. (Pubitemid 351287949)
23. Kuklenyik Z, et al. 2009. Effect of mobile phase pH and organic content on LC-MS analysis of nucleoside and nucleotide HIV reverse transcriptase inhibitors. J. Chromatogr. Sci. 47:365-372.
24. Mahalingam A, et al. 2011. Vaginal microbicide gel for delivery of IQP- 0528, a pyrimidinedione analog with a dual mechanism of action against HIV-1. Antimicrob. Agents Chemother. 55:1650-1660.
25. Malcolm K, et al . 2010. Pre-treatment with Depo-Provera modifies the pharmacokinetics of CMPD167 in rhesus macaques following vaginal ring administration, abstr. 37. Abstr. Microbicides 2010, Pittsburgh, PA.
26. Malcolm K, et al. 2003. Influence of silicone elastomer solubility and diffusivity on the in vitro release of drugs from intravaginal rings. J. Control. Release 90:217-225. (Pubitemid 36694965)
27. Miller L, MacFarlane SA, Materi HL. 2005. A scanning electron microscopic study of the contraceptive vaginal ring. Contraception 71:65-67. (Pubitemid 41583152)
28. Mitchell C, et al. 2011. Estimating volume of cervicovaginal secretions in cervicovaginal lavage fluid collected for measurement of genital HIV-1 RNA levels in women. J. Clin. Microbiol. 49:735-736.
29. Morris GC, Lacey CJ. 2010. Microbicides and HIV prevention: lessons from the past, looking to the future. Curr. Opin. Infect. Dis. 23:57-63.
30. Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Landry ML (ed). 2007. Manual of clinical microbiology, 9th ed. ASM Press, Washington, DC.
31. Nel A, et al. 2009. Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. J. Acquir. Immune Defic. Syndr. 51:416-423.
32. Owen DH, Katz DF. 1999. A vaginal fluid simulant. Contraception 59: 91-95. (Pubitemid 29244754)
33. Parikh UM, et al. 2009. Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J. Virol. 83: 10358-10365.
34. Patton DL, Cosgrove Sweeney YT, Paul KJ. 2008. A summary of preclinical topical microbicide vaginal safety and chlamydial efficacy evaluations in a pigtailed macaque model. Sex. Transm. Dis. 35:889-897.
35. Patton DL, Sweeney YC, Rabe LK, Hillier SL. 1996. The vaginal microflora of pig-tailed macaques and the effects of chlorhexidine and benzalkonium on this ecosystem. Sex. Transm. Dis. 23:489-493. (Pubitemid 26391573)
36. Promadej-Lanier N, et al. 2009. Development and evaluation of a vaginal ring device for sustained delivery of HIV microbicides to non-human primates. J. Med. Primatol. 38:263-271.
37. Rabe LK, Hillier SL. 2003. Optimization of media for detection of hydrogen peroxide production by Lactobacillus species. J. Clin. Microbiol. 41: 3260-3264. (Pubitemid 36842331)
38. Romano J, et al. 2009. Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring. AIDS Res. Hum. Retroviruses 25:483-488.
39. Saltzman WM. 2001. Drug delivery: engineering, principles for drug therapy. Oxford University Press, New York, NY.
40. Sivin I, et al. 1997. Contraceptives for lactating women: a comparative trial of a progesterone-releasing vaginal ring and the copper T 380A IUD. Contraception 55:225-232. (Pubitemid 27435168)
41. Srivastava P, et al. 2004. Optimization of unique, uncharged thioesters as inhibitors of HIV replication. Bioorg. Med. Chem. 12:6437-6450. (Pubitemid 39535167)
42. Tang L, Khan SU, Muhammad NA. 2001. Evaluation and selection of bio-relevant dissolution media for a poorly water-soluble new chemical entity. Pharm. Dev. Technol. 6:531-540. (Pubitemid 34014961)
43. Thomas C. 2009. Roadblocks in HIV research: five questions. Nat. Med. 15:855-859.
44. UNAIDS. 2010. Report on the global AIDS epidemic. UNAIDS, Geneva, Switzerland.
45. Van Rompay KK. 2010. Evaluation of antiretrovirals in animal models of HIV infection. Antiviral Res. 85:159-175.
46. Veazey RS. 2008. Microbicide safety/efficacy studies in animals: macaques and small animal models. Curr. Opin. HIV AIDS 3:567-573.
47. Woolfson AD, et al. 2006. Potential use of vaginal rings for prevention of heterosexual transmission of HIV: a controlled-release strategy for HIV microbicides. Am. J. Drug Deliv. 4:7-20.